Peptides with Neuroprotective Properties, Identified in Early Study, May Help Alzheimer’s Patients

Peptides with Neuroprotective Properties, Identified in Early Study, May Help Alzheimer’s Patients
A family of six mitochondrial small humanin-like peptides (SHLPs) showed promising effects on cell survival and metabolism in preclinical studies of aging, a finding with long-reaching implications for age-related conditions such as Alzheimer’s disease. The findings were announced by the biotechnology company CohBar, which holds the exclusive license for developing SHLPs into therapeutics, in a press release. Performed by scientists at the University of Southern California (USC) and the Institute for Aging Research at the Albert Einstein College of Medicine of Yeshiva University, the studies showed that SHLP2 – one of the peptides whose levels decline with age — had properties that could be beneficial in the treatment of Alzheimer’s disease. The research article, “Naturally Occurring Mitochondrial-derived Peptides are Age-dependent Regulators of Apoptosis, Insulin Sensitivity, and Inflammatory Markers,” was published in the journal Aging. Findings also indicated that SHLPs could be used in treatment approaches for diabetes and cancer, as the peptide family is associated with neuroprotective and anti-inflammatory characteristics, and alters metabolic functions of cells. The family of SHLPs was identified using a computer-based analysis of the mit
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *